DRESS Syndrome is a severe, adverse, hypersensitivity reaction to prescription drugs that causes life-threatening, progressive symptoms. The condition is also known as Drug-Induced Hypersensitivity Syndrome (DIHS).
One in every 1,000 to 10,000 medication exposures will result in DRESS. While most people recover from DRESS, 10% of patients will die from this disease.
By coming together in our first global and virtual DRESS Syndrome meeting, we aim to unite the research and medical communities with the DRESS Syndrome community and deepen our understanding of this relatively unknown condition.
If you are a DRESS survivor or have lost a loved one to DRESS Syndrome, we invite you to join us. Sharing your experiences will help contribute to the discussion on unmet clinical and research needs.
The conference is a virtual two-day event, and registration is complimentary.
Meeting highlights include:
Professor of Medicine, Dermatology, Pathology, Microbiology Professor of Pharmacology John A. Oates Chair in Clinical Research Center for Drug Safety and Immunology Vanderbilt University Medical Center
Dr. Phillips is a world leader in translational approaches to drug hypersensitivity and has pioneered the discovery and implementation of immunogenomic predictors, immunopathogenesis and novel technologies to improve the safety of drugs into clinical practice. She has a clinical practice dedicated to drug hypersensitivity and has led clinical and research programs in SJS/TEN and other severe immune-mediated adverse drug reactions across different medical systems for over 25 years. She is PI on NIH funded research to define genetic and other markers to lead to prediction and prevention earlier diagnosis and to define the most effective treatment. She has been a great advocate of integration and engagement of the community in science. In addition to being a Chair of SJSTEN 2021 she also founded and chaired the 2017 and 2019 meetings.
Head, Inflammatory and Autoimmune Skin Diseases Unit, Dermatology Department, Emek Medical Center, Israel; Assistant Professor- Status Only, Department of Medicine, University of Toronto, Canada
Dr. Dodiuk-Gad is a clinician, researcher, educator, and opinion leader in Dermatology on the topics of adverse cutaneous drug reactions and Darier disease. She mentors students and residents both in Israel and Canada and leads several research teams focusing specifically on these topics. Dr. Dodiuk-Gad graduated from the Technion and conducted clinical and research fellowships in the University of Toronto. She is currently an Assistant Professor in both these institutes, the Head of the Dermatology Program Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Israel and the Head of Inflammatory and Autoimmune Skin Diseases Unit, Dermatology Department, Emek Medical Center, Israel. Dr. Dodiuk-Gad initiated several global educational platforms in Dermatology, and she is engaged in major international collaborations.
Chief of Dermatology, Kansas University Medical Center
Dr. Adela Rambi G. Cardones is the Dermatology Division Chief and is a Tenured Professor at the University of Kansas Medical Center. She completed a research fellowship in immunology at the National Institutes of Health, in Bethesda MD, and her residency training in Dermatology at Duke University Medical Center. She received her Masters' Degree in Clinical Research through the Duke-NIH Clinical Research Training Program. She was the Director of Inpatient Dermatology at Duke University from 2010-2022, during which she also attained the rank of Tenured Associate Professor in the Department of Dermatology. Dr. Cardones has interest and expertise in Complex Medical Dermatology and Immunodermatology, including severe cutaneous drug reactions, autoimmune and fibrosing disorders, and graft-versus-host disease.
DRESS Syndrome Foundation is a nonprofit dedicated to providing DRESS patients with medical advocacy and support. They also work to deepen medical research and awareness of this disease.
HHV-6 Foundation is a nonprofit institution that encourages scientific exchange about HHV-6 infection between investigators by holding conferences, facilitating research, and offering pilot grants. They also raise awareness among physicians of other medical conditions associated with HHV-6 infection.